Saltar al contenido
Merck

Efficient inhibition of human glioma development by RNA interference-mediated silencing of PAK5.

International journal of biological sciences (2015-01-30)
Xuefeng Gu, Ce Wang, Xuefeng Wang, Guoda Ma, You Li, Lili Cui, Yanyan Chen, Bin Zhao, Keshen Li
RESUMEN

Glioma is the most common type of primary intracranial tumor and is highly lethal due to its pathogenetic location, high invasiveness, and poor prognosis. Even combined surgery and chemoradiotherapy do not effectively rescue glioma patients. Molecular target therapy is considered a safe and promising therapy for glioma. The identification of a novel, effective target protein in gliomas is of great interest. We found that PAK5 was highly expressed in the tumor tissues of glioma patients and human glioma cell lines. We then used a lentivirus-delivered short hairpin RNA to stably silence PAK5 expression in glioma cells and explore its influence. The results showed that the inhibition of PAK5 reduced cell viability and delayed the cell cycle at the G0/G1 phase in the glioma cells with PAK5 high expression. In addition, silencing PAK5 expression in U87 cells weakened their colony formation ability and in vivo tumorigenesis ability. Further studies demonstrated that PAK5 inhibition led to an increase in cleaved caspase 3 and a decrease in β-catenin. In conclusion, our results suggest that the inhibition of PAK5 by RNA interference might efficiently suppress tumor development of glioma cells with PAK5 high expression. This finding provides a novel, promising therapeutic target for glioma treatment.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Azul de tiazolil Bromuro de tetrazolio, 98%
Sigma-Aldrich
Azul de tiazolil Bromuro de tetrazolio, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥97.5% (HPLC)
Sigma-Aldrich
Yoduro de potasio, ≥94.0% (HPLC)
Sigma-Aldrich
Propidium iodide solution
Sigma-Aldrich
Yoduro de potasio, ≥94% (HPLC)